Correlation of Prostate-specific Antigen Kinetics with Overall Survival and Radiological Progression-free Survival in Metastatic Castration-sensitive Prostate Cancer Treated with Abiraterone Acetate plus Prednisone or Placebos Added to Androgen Deprivation Therapy: Post Hoc Analysis of Phase 3 LATITUDE Study
Publication date: Available online 13 December 2019Source: European UrologyAuthor(s): Nobuaki Matsubara, Kim N. Chi, Mustafa Özgüroğlu, Alfredo Rodriguez-Antolin, Susan Feyerabend, Luis Fein, Boris Y. Alekseev, Giri Sulur, Andrew Protheroe, Susan Li, Suneel Mundle, Peter De Porre, Namphuong Tran, Karim FizaziAbstractBackgroundLATITUDE, a randomized, double-blind trial, compared abiraterone acetate and prednisone (AAP) + androgen deprivation therapy (ADT) versus placebo (PBO) + ADT in high-risk metastatic castration-sensitive prostate cancer (mCSPC).ObjectiveTo assess the correlation of prostate-specific antigen (PSA) kinetics with overall survival (OS) and radiological progression-free survival (rPFS).Design, setting, and participantsA post hoc analysis of data from 597 men receiving AAP + ADT and 602 receiving PBO + ADT.Outcome measurements and statistical analysisThe associations of PSA-related outcomes (rates of confirmed 50% [PSA50] and 90% [PSA90] decline from baseline PSA [Prostate Cancer Working Group 2 criteria], rates of PSA
Publication date: Available online 16 January 2020Source: Molecular Aspects of MedicineAuthor(s): Delila Gasi Tandefelt, Johann de BonoAbstractOnly in the past decade tremendous advances have been made in understanding prostate cancer genomics and consequently in applying new treatment strategies. As options regarding treatments are increasing so are the challenges in selecting the right treatment option for each patient and not the least, understanding the optimal time-point and sequence of applying available treatments. Critically, without reliable methods that enable sequential monitoring of evolving genotypes in indivi...
Prostate Cancer and Prostatic Diseases, Published online: 17 January 2020; doi:10.1038/s41391-020-0205-7A noninferiority within-person study comparing the accuracy of transperineal to transrectal MRI–US fusion biopsy for prostate-cancer detection
ConclusionIn this series of patients, we have shown that metastatic LNs can be safely treated with image-guided CA. Caution should be paid, and additional measures should be taken when treating LNs near thermal-sensible structures.
A new analysis provides estimates of bowel, bladder, and sexual function through five years following contemporary treatments for localized prostate cancer, which may help men clarify expectations and make more informed treatment choices, the research team says.Reuters Health Information
Behavioral intervention had no impact on time to progression among men with early - stage disease
Conclusion 68Ga-PSMA PET-CT allows accurate detection of lymphnodal metastases in patients with intermediate-risk and high-risk prostate cancer prior to definitive surgical treatment. It performed better than mp-MRI in a subset of patients.
Conclusion Our study demonstrated that visual report of [18F]FCH PET/CT was very reproducible and that the repeatability limits of SUVmax was similar to those of other PET radiotracers. An SUVmax difference of more than 40% should be considered as representing a treatment response effect. Change of SUVmax during the acquisition time varied and should not be considered as an interpretation criterion.
Authors: Wu Z, Xu X, Dai L, Wang Y, Yang B, Zhao H, Lou C Abstract Eupalinolide J (EJ) is a new sesquiterpene lactone isolated from Eupatorium lindleyanum DC. In the present study, we investigated the anti-cancer activity of EJ on cell proliferation in human prostate cancer cells. The MTT results indicated that EJ showed marked anti-proliferative activity in PC-3 and DU-145 cells in a dose- and time-dependent manner. DAPI staining analysis demonstrated that this effect was mediated by induction of cell apoptosis. Flow cytometric analysis indicated a significant increase in apoptotic cells, cell cycle arrest at G0/G...
This sixth annual report presents the results for patients diagnosed with prostate cancer between 1st April 2017 and 31st March 2018 in England and Wales. It is accompanied by provider results and an infographic.